A federal deadline is now eight weeks away for one of the largest rounds yet of Medicare’s drug price negotiations. By November 1, 2026, the Centers for Medicare & Medicaid Services and the manufacturers of 15 brand-name drugs must close out bargaining over what Medicare will pay for those medicines, under the third cycle of the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act. Whatever prices come out of that deadline will not appear at a pharmacy counter for more than a year afterward, since they apply starting with the 2028 Medicare plan year, not this fall’s enrollment season or 2027 premiums. For a Medicare beneficiary trying to plan a household budget, the calendar between now and 2028 matters as much as which drugs are on the list.
The November 1 Deadline Written Into CMS’s Own Calendar
CMS selected the 15 drugs, covered under Medicare Part B and Part D, on January 27, 2026, along with one additional drug chosen for renegotiation of an earlier round’s price. Every manufacturer with a selected drug agreed to take part, a decision CMS confirmed on March 13, 2026. That single yes-or-no choice mattered: the law lets CMS impose steep excise taxes or force a manufacturer out of Medicare and Medicaid altogether if it refuses to negotiate, so participation itself was never the open question. The open question is the price. CMS’s published milestone schedule shows the two sides have been trading offers for months: CMS sent an initial offer to each participating company by June 1, 2026, each company had 30 days to accept or counter, and negotiators get up to two additional meetings through the summer before the clock runs out. The schedule sets September 11, 2026, as the last day for a negotiation meeting and September 30, 2026, as CMS’s deadline to send a final offer if no deal has been struck by then. Manufacturers have until October 31, 2026, to accept or reject that final number, one day before the entire negotiation and renegotiation period legally ends on November 1, 2026.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
What Actually Happens Between the Deadline and January 2028
Passing November 1 does not, by itself, put a number in front of the public. CMS’s own fact sheet on the third round of negotiations lays out what comes next: the agency has until November 30, 2026, to publish any maximum fair prices it reached agreement on, and until March 1, 2027, to release a fuller written explanation of how each price was calculated for the drugs where a deal was struck. Only after that does the new pricing take effect, on January 1, 2028, the start of the plan year CMS refers to as the "initial price applicability year" for this third cycle. Nothing in that sequence changes what a beneficiary pays this year or next for any of the affected drugs; the entire process now underway sets a price that has not yet been fixed and will not be usable at a pharmacy or under Part B billing until 2028 arrives. Framing this as a completed price cut, rather than a deadline for reaching one, would misstate where the process actually stands as of today.
How CMS Narrowed Medicare’s Costliest Drugs to This List
The 15 selected drugs were not picked for medical reasons alone. Federal law requires CMS to rank single-source drugs with no generic or biosimilar competitor by total Medicare Part B and Part D spending, after excluding certain orphan drugs, low-spend drugs, and plasma-derived products, then choose the highest-spending ones left standing. Over the twelve months CMS used to build this year’s list, from November 2024 through October 2025, an estimated 1,777,000 people with Medicare Part B and/or Part D coverage used the 15 drugs now under negotiation, and Medicare spent about $27.0 billion on them, roughly 6% of all Part B and Part D drug spending in that window. The top two by spending, the diabetes and cardiovascular drug Trulicity at $4.9 billion and the HIV treatment Biktarvy at $3.9 billion, illustrate how concentrated that spending is among a small number of medicines used by hundreds of thousands of enrollees. CMS is also holding patient-focused roundtables and a clinical town hall this year so patients, caregivers, and clinicians can weigh in on how the selected drugs are used before any price is finalized.
Two Earlier Rounds Already Reset Prices for 2026 and 2027
This third cycle is not Medicare’s first attempt at direct negotiation. CMS reached agreement on negotiated prices for 10 drugs in the program’s first cycle, and those prices have applied since January 1, 2026. A second cycle covering 15 more drugs produced negotiated prices that took effect January 1, 2027. CMS has estimated that if the second cycle’s negotiated prices had applied during 2024, they would have saved an estimated $12 billion in net covered prescription drug costs, or about $8.5 billion once the manufacturer discounts already required under the Coverage Gap Discount Program are factored in. Those two completed rounds are the evidence that this process produces real, binding prices rather than a symbolic negotiation; they are also the clearest sign of what is not yet true of the drugs selected for this third round, since no comparable savings estimate exists for 2028 because no price has been agreed to.
What Changes for a Beneficiary’s Budget Right Now, and What Does Not
For a retiree currently taking one of the 15 drugs, or a household budgeting around one, the practical answer this fall is that nothing changes yet. Coverage, formulary status, and out-of-pocket costs for these drugs through the rest of 2026 and all of 2027 are governed by existing plan pricing and by the separate $2,000 annual out-of-pocket cap already in place for Part D enrollees, not by anything from this negotiation. The number that will eventually matter, the negotiated maximum fair price, does not exist publicly yet and will not until CMS meets its November 30, 2026 publication deadline at the earliest, with the fuller accounting due by March 1, 2027. CMS’s own milestone schedule, not a manufacturer statement or a lobbying estimate, is the document that will confirm whether these 15 drugs get a negotiated price at all, and readers tracking the outcome have a specific date to watch rather than a vague promise of future savings.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- What really happens to your joint savings account when you die?
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
